Obsidian Therapeutics enrols first patient in phase 1/2 Agni-01 study to evaluate Amsoki-cel in advanced melanoma: Cambridge, Massachusetts Saturday, August 8, 2026, 18:00 Hrs [IS ...
UK MHRA grants marketing authorization to Novartis Rhapsido for adult patients with CSU with inadequate response to H1 antihistamine: London Saturday, August 8, 2026, 09:00 Hrs [I ...
Union Minister of State (I/C) for Ayush, P Jadhav in a written reply in Lok Sabha stated that the Ministry of Ayush has launched several initiatives to promote the production, quality, research, ...
Mediar Therapeutics inks collaboration and option agreement with Ono Pharma to develop novel treatments for fibro-inflammatory diseases: Boston Saturday, August 8, 2026, 11:00 Hrs ...
Lucid Diagnostics secures commercial coverage policy spanning multiple health plans for its EsoGuard esophageal DNA test: New York Saturday, August 8, 2026, 13:00 Hrs [IST] Lucid ...
Govt strengthens affordable healthcare ecosystem through NHM, AB PM-JAY: Anupriya Patel: Our Bureau, Mumbai Saturday, August 8, 2026, 13:15 Hrs [IST] Union minister of state for h ...
Ractigen Therapeutics completes enrollment and first dosing in phase II trial of RAG-17 for SOD1-ALS: Nantong, China Saturday, August 8, 2026, 10:00 Hrs [IST] Ractigen Therapeutic ...
Emergent BioSolutions highlights for a cross-sector collaboration against biological threats in evolving global security environ: Gaithersburg, Maryland Saturday, August 8, 2026, ...
Dispatch Bio begins patient dosing in phase 1 study of DISP-10, a novel investigational immunotherapy, in advanced gastrointestinal cancers: Philadelphia, San Francisco Saturday, ...
Evotec and Odyssey Therapeutics ink AI-enabled R&D collaboration in autoimmune and inflammatory diseases: Hamburg, Germany Saturday, August 8, 2026, 15:00 Hrs [IST] Evotec SE, a l ...
NHA achieves milestone with 25 crore OPD registrations through ABHA-based Scan and Register Service: Our Bureau, Mumbai Saturday, August 8, 2026, 13:45 Hrs [IST] In a significant ...
Priovant initiates patient enrolment in phase 3 study of brepocitinib in cutaneous sarcoidosis: Durham, North Carolina Saturday, August 8, 2026, 12:00 Hrs [IST] Priovant, a biotec ...